Drug Profile
Research programme: Streptococcus vaccine and antibody therapeutics - Valneva
Alternative Names: Group A Streptococcus antibodies - Intercell; Group A Streptococcus antibodies - Valneva; Group A Streptococcus vaccine - Intercell; Group A Streptococcus vaccine - Valneva; Group B Streptococcus antibodies - Intercell; Group B Streptococcus antibodies - ValnevaLatest Information Update: 01 Jul 2013
Price :
$50
*
At a glance
- Originator Intercell
- Developer Valneva
- Class Monoclonal antibodies; Streptococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Streptococcal infections
Most Recent Events
- 01 Jul 2013 No development reported - Preclinical for Streptococcal infections in Austria (Parenteral)
- 28 May 2013 Intercell has merged with Vivalis to form Valneva
- 01 Sep 2010 Preclinical development is ongoing with Intercell